Lamp2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Symbol | LAMP2 |
| Full Name | Lysosomal Associated Membrane Protein 2 |
| Chromosomal Location | Xq24 (ChrX: 119,769,452-119,810,423) |
| NCBI Gene ID | 3990 |
| OMIM | 300256 |
| Ensembl ID | ENSG00000143106 |
| UniProt | P13473 |
LAMP2 encodes Lysosomal Associated Membrane Protein 2, a major lysosomal membrane glycoprotein essential for lysosomal function, autophagy, and chaperone-mediated autophagy (CMA).
The study of Lamp2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Key publications linked throughout this page.
LAMP2 demonstrates broad tissue distribution with particularly high expression in:
In the brain, LAMP2 is highly expressed in neurons, astrocytes, and microglia, where it plays critical roles in lysosomal function and autophagy.
The LAMP2 gene produces multiple isoforms through alternative splicing:
Each isoform has distinct tissue distribution and functional properties.
LAMP2A forms multimeric complexes in the lysosomal membrane that recognize proteins containing a specific pentapeptide motif (KFERQ). This allows selective degradation of cytosolic proteins without membrane disruption.
LAMP2 participates in general autophagosome-lysosome fusion, though this function is more associated with LAMP2B.
LAMP2 helps target intracellular pathogens for lysosomal degradation, contributing to cellular defense.
LAMP2 mutations cause Danon disease, an X-linked lysosomal storage disorder characterized by:
Reduced LAMP2 expression has been observed in PD brains, potentially contributing to:
LAMP2 involvement in AD includes:
LAMP2 alterations may contribute to ALS pathogenesis through:
| Approach | Description | Development Status |
|---|---|---|
| Gene therapy | AAV-LAMP2 delivery | Clinical trials (Danon) |
| Small molecules | Autophagy enhancers | Preclinical |
| Protein replacement | Recombinant LAMP2 | Experimental |
| Chaperones | Enhance CMA activity | Research |
LAMP2 knockout mice exhibit:
These models have been valuable for understanding LAMP2 function and testing therapeutic approaches.
[^3 et al. (2006). "Chaperone-mediated autophagy: A unique pathway for protein quality control." Biochemical Society Transactions 34(5): 749-753.
Saftig P, et al. (2008). "LAMP-2 deficiency: from Danon disease to neurodegeneration." EMBO Molecular Medicine 1(2): 82-87]: Massey AC,. ↩︎
Cuervo AM, et al. (2004). "Impairment of chaperone-mediated autophagy in aging and neurodegeneration." Aging Cell 3(6): 313-317. ↩︎
Rothenberg C, et al. (2010). "LAMP2 improves cellular function in models of Parkinson's disease." Autophagy 6(8): 1153-1161. ↩︎
Wang Y, et al. (2016). "LAMP2 in Alzheimer's disease and related disorders." Journal of Alzheimer's Disease 51(4): 1021-1032. ↩︎